WASHINGTON, D.C., June 11 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY - News) today announced encouraging results from an analysis of pooled data from two, three-year phase 3 trials that showed ruboxistaurin mesylate reduced the risk of sustained moderate vision loss by 41 percent when compared to placebo in patients with moderate to severe, nonproliferative diabetic retinopathy (DR). Vision loss occurred in only 6.1 percent of patients treated with ruboxistaurin compared to 10.2 percent of patients treated with placebo.(1) Ruboxistaurin (proposed brand name Arxxant(TM)) is an investigational drug for the treatment of DR, a diabetic eye disease.
